David Kirk is a freelance writer and communications consultant with interests in synthetic biology, biotech, and sustainability. He has a PhD in molecular microbiology and has industrial experience developing living medicines.

Articles by David Kirk

In Depth 22 Jul 2020

Artificial Intelligence: A Superpower in the Fight Against Covid-19

Chilean Biotech Moves to France to Develop Anti-Mold Food Preservative

UK Startup Launches with €10M to Detect Epigenetic Signs of Cancer in Blood

AI Drug Discovery Firm Exscientia Closes €54M Series C

Synthetic Biology Could Lead to Clean Energy Using Light and Carbon Dioxide


EU Pitches Into €7.4B Fund Supporting Covid-19 Treatments & Vaccines

AskBio Takes Over French Gene Therapy Company to Treat Alzheimer’s and Huntington’s

Anti-Aging Treatments at Forefront of Astellas’ €80M UK Acquisition

UK Startup to Manufacture Cell and Gene Therapies with Microfluidics

Two European Alzheimer’s Disease Treatments Show Promise in Phase II

UK Biotech’s Arthritis Drug Enters Study in Coronavirus Patients